Complacency in GERD an Imminent Disaster


  • Jibran Umar Ayub Khan Department of Medicine, Kabir Medical College, Peshawar
  • Azhar Zahir Shah Department of Surgery, Kabir Medical College Peshawar
  • Ayesha Qaisar Department of Physiology, Khyber Medical College Peshawar



Gastroesophageal reflux disease is one of the most common gastrointestinal disorders which is mainly characterized by problems with esophageal peristalsis, which is responsible for propelling food from the esophagus into the stomach or dysfunctional or weaker lower esophageal sphincter, which prevents the reflux to stomach contents.Typical symptoms involve heartburn, regurgitation of food, a sore taste in the mouth, and sometimes atypical symptoms like chest pain, signs of dental erosion and even breathlessness at night. There is also a trend of testing for helicobacter pylori in GERD patients which is absolutely not recommended at all as there is no evidence that eradication therapy will ease the symptoms.Instead, it has contributed to widespread antimicrobial resistance with physicians using them, which is otherwise a futile exercise. There is no need to try different proton pump inhibitors for a long time when there is no improvement in symptoms.The physicians in general practice should rather be generous in referring such patients on time to gastroenterology experts, as the treatment needs to be multidisciplinary and one should not be silent on sinister signs and symptoms if they are present. Endoscopy is already a safer option to screen such patients, which will suffice for the reassurance of the patients.


Mousa H, Hassan M. Gastroesophageal reflux disease. Pediatr Clin North Am. 2017; 64(3): 487–505. doi:10.1016/j.pcl.2017.01. 003.

Choe JW, Joo MK, Kim HJ, Lee BJ, Kim JH, Yeon JE, et al. Foods inducing typical gastroesophageal reflux disease symptoms in Korea. J Neurogastroenterol Motil. 2017; 23(3): 363–369. doi:10.5056/jnm16122

Azzam RS. Are the persistent symptoms to proton pump inhibitor therapy due to refractory gastroesophageal reflux disease or to other disorders? Arq Gastroenterol. 2018; 55(Suppl-1): 85–91. doi:10.1590/S0004-280 3.201800000-48.

Gyawali CP, Fass R. Management of gastroesophageal reflux disease. Gastroenterology. 2018; 154(2): 302–318. doi :10.1053/j.gastro.2017.07.049.

Chiang HH, Wu DC, Hsu PI, Kuo CH, Tai WC, Yang SC, et al. Clinical efficacy of 60-mg dexlansoprazole and 40-mg esomeprazole after 24 weeks for the on-demand treatment of gastroesophageal reflux disease grades A and B: A prospective randomized trial. Drug Des Devel Ther. 2019; 13: 1347–1356. doi:10.214 7/DDD T.S193559.

Liang CM, Kuo M Te, Hsu PI, Kuo CH, Tai WC, Yang SC, et al. First-week clinical responses to dexlansoprazole 60 mg and esomeprazole 40 mg for the treatment of grades A and B gastroesophageal reflux disease. World J Gastroenterol. 2017; 23(47): 8395-8404. doi:10.3748/wjg.v23.i47. 8395.

Alexander SM, Retnakumar RJ, Chouhan D, Devi TNB, Dharmaseelan S, Devadas K, et al. Helicobacter pylori in Human Stomach: The Inconsistencies in Clinical Outcomes and the Probable Causes. Front Microbiol. 2021; 12: 713955. doi:10.3389/fmicb.2021.71 3955.

Song JH, Kim YS, Choi SY, Yang SY. Association between gastroesophageal reflux disease and coronary atherosclerosis. PLoS One. 2022; 17(5): e0267053. doi:10.137 1/journal.pone.0267053.

Kalapala R, Karyampudi A, Nabi Z, Darisetty S, Jagtap N, Ramchandani M, et al. Endoscopic full-thickness plication for the treatment of PPI-dependent GERD: Results from a randomised, sham-controlled trial. Gut. 2022; 71(4): 686–694. doi:10.1136 /gutjnl-2020-321811.

Sharma P, Shaheen NJ, Katzka D, Bergman JJGHM. aga clinical practice update on endoscopic treatment of barrett's esophagus with dysplasia and/or early cancer: Expert Review.Gastroenterology.2020; 158(3):760-769. doi:10.1053/j.gas tro.2019. 09.051.




How to Cite

Jibran Umar Ayub Khan, Zahir Shah A, Qaisar A. Complacency in GERD an Imminent Disaster. J Shalamar Med Dent Coll [Internet]. 2023 Jun. 27 [cited 2024 Jun. 13];4(1):1-3. Available from: